Clinical Study

In Vitro Evaluation Of Hemerus Apex™ Additive Solution For Preservation Of Cpda-1 Whole Blood As Compared To Cpda-1 Whole Blood Without Additive Solution

Posted Date: Sep 27, 2022

  • Investigator: Jose Cancelas
  • Specialties:
  • Type of Study: Drug

Hemerus Medical, LLC is developing a new formulation of anticoagulant preservative that will yield similar or improved quality whole blood (WB) providing an extended shelf life to at least 42 days compared to the current 21-day product (Citrate Phosphate Dextrose [CPD] anticoagulant) or 35-day product (Citrate Phosphate Dextrose Adenine [CPDA-1] anticoagulant). The hypothesis is that reformulation of anticoagulant-preservative solution will provide longer shelf life for WB with acceptable red blood cell (RBC) quality, platelet function, and plasma factor stability over the conventional CPDA-1 anticoagulant.

Criteria:

Normal Healthy Blood Donors

Keywords:

Whole Blood Donation, Normal Healthy Blood Donors

For More Information:

Neeta Rugg
5136520104
neeta.rugg@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.